股市必读：健民集团（600976）10月22日主力资金净流出1307.95万元，占总成交额16.59%

Core Viewpoint - The financial performance of Jianmin Group (600976) for the third quarter of 2025 shows a decline in revenue and net profit compared to the previous year, primarily due to a significant drop in pharmaceutical commercial income, despite growth in pharmaceutical manufacturing revenue. Financial Performance Summary - Revenue: The total revenue for the third quarter was approximately 747.33 million yuan, representing a year-on-year decrease of 14.27%. For the year-to-date, revenue was approximately 2.55 billion yuan, down 11.43% from the previous year [3][4]. - Net Profit: The net profit attributable to shareholders was approximately 65.11 million yuan for the quarter, down 20.84% year-on-year. Year-to-date net profit was approximately 285.74 million yuan, a decrease of 11.16% [3][5]. - Cash Flow: The net cash flow from operating activities for the year-to-date increased by 31.45%, amounting to approximately 139.05 million yuan, attributed to increased industrial sales collections [3][4]. Segment Performance - Pharmaceutical Manufacturing: Revenue from pharmaceutical manufacturing increased by 19.67% year-on-year, driven by growth in leading and new products [5]. - Pharmaceutical Commerce: Revenue from pharmaceutical commerce decreased by 36.91%, primarily due to a strategic shift to optimize business structure and reduce low-margin operations [5]. Shareholder Information - The largest shareholder is Huali Pharmaceutical Group Co., Ltd., holding 24.15% of the shares. Other significant shareholders include Hong Kong Central Clearing Limited and Huali Group Co., Ltd. [7]. Market Activity - On October 22, 2025, Jianmin Group's stock closed at 39.77 yuan, down 1.78%, with a turnover rate of 1.29% and a trading volume of 19,800 shares, resulting in a transaction value of approximately 78.86 million yuan [1][2]. - The net outflow of main funds on the same day was approximately 13.08 million yuan, accounting for 16.59% of the total transaction value [2][4].